SpringWorks Therapeutics Return On Equity vs. Current Valuation

SWTX Stock  USD 38.91  2.61  7.19%   
Based on SpringWorks Therapeutics' profitability indicators, SpringWorks Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess SpringWorks Therapeutics' ability to earn profits and add value for shareholders.
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
(0.52)
Current Value
(0.49)
Quarterly Volatility
0.99821995
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, SpringWorks Therapeutics' Price To Sales Ratio is fairly stable compared to the past year. EV To Sales is likely to rise to 411.56 in 2024, whereas Days Sales Outstanding is likely to drop 317.90 in 2024. At this time, SpringWorks Therapeutics' Accumulated Other Comprehensive Income is fairly stable compared to the past year. Interest Income is likely to rise to about 23.3 M in 2024, despite the fact that Operating Income is likely to grow to (325.9 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.960.9225
Sufficiently Up
Slightly volatile
For SpringWorks Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of SpringWorks Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well SpringWorks Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between SpringWorks Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of SpringWorks Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
For more information on how to buy SpringWorks Stock please use our How to Invest in SpringWorks Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of SpringWorks Therapeutics. If investors know SpringWorks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about SpringWorks Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.89)
Revenue Per Share
1.885
Return On Assets
(0.34)
Return On Equity
(0.59)
The market value of SpringWorks Therapeutics is measured differently than its book value, which is the value of SpringWorks that is recorded on the company's balance sheet. Investors also form their own opinion of SpringWorks Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is SpringWorks Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SpringWorks Therapeutics' market value can be influenced by many factors that don't directly affect SpringWorks Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SpringWorks Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if SpringWorks Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SpringWorks Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

SpringWorks Therapeutics Current Valuation vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining SpringWorks Therapeutics's current stock value. Our valuation model uses many indicators to compare SpringWorks Therapeutics value to that of its competitors to determine the firm's financial worth.
SpringWorks Therapeutics is rated below average in return on equity category among its peers. It is rated below average in current valuation category among its peers . At this time, SpringWorks Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SpringWorks Therapeutics' earnings, one of the primary drivers of an investment's value.

SpringWorks Current Valuation vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

SpringWorks Therapeutics

Return On Equity

 = 

Net Income

Total Equity

 = 
-0.59
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

SpringWorks Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
2.42 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

SpringWorks Current Valuation vs Competition

SpringWorks Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 39.54 Billion. SpringWorks Therapeutics holds roughly 2.42 Billion in current valuation claiming about 6% of equities under Health Care industry.

SpringWorks Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in SpringWorks Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, SpringWorks Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of SpringWorks Therapeutics' change in net profit over the period of time. It can combine multiple indicators of SpringWorks Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income1.2 M1.3 M
Operating Income-343 M-325.9 M
Income Tax Expense-22.9 M-21.8 M
Income Before Tax-325.1 M-308.8 M
Net Loss-249.7 M-237.2 M
Net Loss-325.1 M-308.8 M
Interest Income22.1 M23.3 M
Net Loss-305 M-289.7 M
Total Other Income Expense Net17.9 M18.8 M
Net Interest Income22.1 M23.3 M
Change To Netincome88.5 M93 M
Net Loss(5.15)(5.41)
Income Quality 0.69  0.55 
Net Income Per E B T 0.89  0.78 

SpringWorks Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on SpringWorks Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of SpringWorks Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the SpringWorks Therapeutics' important profitability drivers and their relationship over time.

Use SpringWorks Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if SpringWorks Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SpringWorks Therapeutics will appreciate offsetting losses from the drop in the long position's value.

SpringWorks Therapeutics Pair Trading

SpringWorks Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to SpringWorks Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace SpringWorks Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back SpringWorks Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling SpringWorks Therapeutics to buy it.
The correlation of SpringWorks Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as SpringWorks Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if SpringWorks Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for SpringWorks Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your SpringWorks Therapeutics position

In addition to having SpringWorks Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Macroaxis Index Thematic Idea Now

Macroaxis Index
Macroaxis Index Theme
An experimental equal-weighted index theme of selected equities generated based on Macroaxis rating and scoring system. The Macroaxis Index theme has 52 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Index Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for SpringWorks Stock Analysis

When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.